Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005145/en/
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.
“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
Financial terms of the agreement were not disclosed.
About Glympse Bio
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – are potentially tunable to a multitude of diseases and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005145/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Beth Kurth
(617) 584-9650
bkurth@conwaycommsir.com
Arran Attridge, Media
(650) 425-8975
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MVNO Europe calls on the European Commission to enable a true Single Market for mobile connectivity and Internet of Things (IoT) through the Digital Networks Act20.11.2025 10:56:00 EET | Press release
The upcoming legislative proposal for a Digital Networks Act (DNA) marks a defining moment for the European Union to build a true Single Market for electronic communications based on openness, competition and innovation. MVNO Europe believes the upcoming DNA should build on the achievements of the existing EU regulatory framework by strengthening competition among diverse providers. This competition drives innovation and delivers tangible benefits for European consumers and businesses. Ensuring genuine choice for end users is essential to maintain Europe’s global competitiveness. In light of the DNA, MVNO Europe stresses the importance of preserving and reinforcing key aspects of the European Electronic Communications Code (EECC): Maintaining the Significant Market Power (SMP) regime is essential to safeguard competition. MVNO Europe calls for the express ability to apply SMP rules to any markets, including mobile markets, as it is vital to prevent abuse of dominant market positions an
Breker Verification Systems and Frontgrade Gaisler Collaborate on High-Reliability RISC-V Fault Tolerant Processor Core20.11.2025 10:00:00 EET | Press release
Breker Verification Systems, whose portfolio solves challenges across the functional verification process for large, complex semiconductors and Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions today confirmed its RISC-V functional verification solutions were pivotal for verification of the NOEL-V, one of Frontgrade Gaisler’s fault-tolerant RISC-V processor IP cores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120600508/en/ “The development of Frontgrade Gaisler’s IP cores is guided by a philosophy that does not tolerate design issues,” notes Jan Andersson, Director of Engineering at Frontgrade Gaisler. “This demands the most robust verification environment, something Breker’s verification solution has contributed to improve, with its broad range of tests and in-depth corner case coverage.” The ultra-high verification coverage afforded by Brek
Verne and Nscale Announce 15MW AI Infrastructure Deployment to Accelerate Sustainable AI Infrastructure Growth in the Nordics20.11.2025 10:00:00 EET | Press release
Verne, the leading provider of low-carbon high-performance data centres across the Nordics, has signed a 15-megawatt agreement with Nscale, the hyperscaler engineered for AI. This collaboration marks a significant step in expanding sustainable AI capacity in Europe. The agreement will feature approximately 4,600 NVIDIA Blackwell Ultra GPUs deployed across Verne’s Icelandic campus throughout 2026. The configuration will be 85 percent liquid-cooled and 15 percent air-cooled, optimised for efficiency and density within Verne’s existing infrastructure. This project is one of the region’s largest liquid-cooled GPU installations, setting a new standard for sustainable high-performance computing by reducing energy use and environmental impact. Dominic Ward, CEO, Verne, said: “The pace of change in AI infrastructure is extraordinary. As the demand for GPU capacity accelerates, availability of clean, renewable power has become as important as raw performance. Partnering with Nscale, whose exper
Yagi & Co., Ltd.: Exhibiting for the first time at ISPO Munich 2025, the world's largest trade fair for sports goods, based in Germany20.11.2025 10:00:00 EET | Press release
Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will be exhibiting for the first time at ISPO Munich, held in Munich, Germany, over three days from Sunday 30th November to Tuesday 2nd December this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119473772/en/ Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new products that address a wide range of health issues in areas such as sleep, beauty and sports through their blood circulation-promoting effects. About ISPO Based in Germany, it is one of the world's largest trade fairs spe
U.S. Original Equipment Automotive Industry Must Transform and Collaborate for Future Resilience and Relevance Finds Joint Research by Arthur D. Little and MEMA OE Suppliers20.11.2025 10:00:00 EET | Press release
At a time of unprecedented volatility, the U.S. original equipment (OE) automotive industry is at an inflection point. Building resilience and driving reshoring requires concerted actions from policymakers, original equipment manufacturers and suppliers. This is the key message from Turbocharging US Automotive Manufacturing Competitiveness, an in-depth Arthur D. Little (ADL) landmark study, carried out in conjunction with industry body MEMA Original Equipment Suppliers. The study draws on research from over 100 global OE automotive suppliers with major U.S. presence and more than 30 interviews with C-suite executives of leading global OE automotive suppliers. Based on ADL analysis, the research provides clear recommendations for transforming the industry to strengthen supply chain resilience and underpin national competitiveness and global relevance. High import dependence exposes the U.S. OE automotive supply chain to cost volatility and geopolitical risk. Current reshoring efforts, d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom